CClinicalTrials.gg
CompletedNCT03615820Updated Aug 6, 2018

Niosomal Propolis as Oromucoadhesive Film: In-vitro, Ex-vivo & In-vivo Investigations

A Phase 1 interventional study of Niosomal PPE oromucoadhesive film and Oromucoadhesive film in Drug Effect and Drug Effect Prolonged, sponsored by British University In Egypt. Completed at 2 sites in Egypt. Open to participants aged 40 Years to 45 Years. Per ClinicalTrials.gov, last updated 2018-08-06.

Sponsored by British University In Egypt · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
40 Years to 45 Years
Sex
All
01

Study summary

A total of 24 patients suffering from RAU, they were divided into two groups each included 12 patients. The first group was treated by the propolis mucoadhesive film and the second group received the film without the active component (placebo group).Patients were handed a checklist for monitoring the actual improvement of the clinical parameters which included; duration of disappearance of pain after film application (hours), duration of complete healing of the aphthous ulcer (weeks), onset of ulcer size reduction after film application (days), duration of propolis film adherence onto the oral mucosa (hours) and finally the level of patient satisfaction scaled from 1-10.

Read the detailed description

The present study have been performed on a total of 24 patients suffering from RAU, they were divided into two groups each included 12 patients. The first group was treated by the propolis mucoadhesive film and the second group received the film without the active component (placebo group). Patients were recruited from the out-patient clinic of the Faculty of Dentistry, British University in Egypt during a period of 6 months.

Patients were subjected to thorough clinical examination and history obtaining in order to diagnose the oral ulcer by an oral medicine specialist, they were thoroughly informed about the study and only those with the oral ulcer within the first day to the third day of appearance were included in the present study.

The exclusion criteria in the present study were the presence of systemic or local disease such as hepatitis, cardiac conditions, hypertension, diabetes mellitus, renal problems, mental disorders, AIDS and also the use of any immunosuppressive drugs or systemic corticosteroids during last three months or using steroid treatment locally in last month, also any nutritional supplements, folic acid or antioxidants, pregnancy and nursing.

All patients were asked to avoid using antiseptics, antibiotics or analgesics, during the study as they might aid in curing the oral ulcers. Patients were blinded of receiving either propolis or placebo. They were warned about the potentiality of allergic responses that could happen to some people and that in case of occurrence of such side effect immediate termination of using the film should be implemented.

The patients were first instructed how to apply the mucoadhesive film of 2 cm2 on the oral ulcer and pasted by applying a light force with the finger tip for 20 s, and then were asked to apply it two times per day and to refrain from eating for at least one hour after the film application on the oral ulcer.

Patients were handed a checklist for monitoring the actual improvement of the clinical parameters which included; duration of disappearance of pain after film application (hours), duration of complete healing of the aphthous ulcer (weeks), onset of ulcer size reduction after film application (days), duration of propolis film adherence onto the oral mucosa (hours) and finally the level of patient satisfaction scaled from 1-10. After total healing of the oral RAU, checklists were recollected from patients, the results were tabulated and statistical analysis were conducted.

02

Conditions studied

  • Drug Effect
  • Drug Effect Prolonged

Keywords

  • Nanovesicles
  • Aphthous ulcer
03

In context

Lead sponsor

British University In Egypt is the lead sponsor of 67 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients suffer from aphthous ulcer

Exclusion criteria

Exclusion Criteria:

  • Chronic diseases ,
  • Hospitalized
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Niosomal PPE oromucoadhesive film

    Niosomal PPE oromucoadhesive film in which PPE entrapped in niosomes then incorporated in oromucoadhesive films

    Drug: Niosomal PPE oromucoadhesive film · Drug: Oromucoadhesive film

  • Placebo comparator
    Oromucoadhesive film

    Oromucoadhesive film that has no niosomal PPE in its content

    Drug: Niosomal PPE oromucoadhesive film · Drug: Oromucoadhesive film

Interventions

  • DrugNiosomal PPE oromucoadhesive film

    Niosomal PPE oromucoadhesive film in which Propolis entrapped in niosomal vesicles and incorporated in oromucoadhesive film

  • DrugOromucoadhesive film

    Oromucoadhesive film without PPE control testing which represents Placebo group

06

What researchers measure

Primary outcomes

  1. Determination of the onset of ulcer size reduction

    Niosomal PPE in oromuco-adhesive film was prepared \& given to 12 patients to examine the onset of ulcer size reduction The patients were first instructed how to apply the mucoadhesive film of 2 cm2 on the oral ulcer and then they were handed a checklist for monitoring the actual improvement that was indicated by the reduction of the size of ulcer.

    Time frame: Fifteen Days

Secondary outcomes

  1. Duration of complete ulcer healing

    oromuco-adhesive film was prepared \& given to 12 patients to examine the duration of complete healing.The patients were first instructed how to apply the mucoadhesive film of 2 cm2 on the oral ulcer and then they were handed a checklist for monitoring the actual improvement that was indicated by the complete healing of ulcer.

    Time frame: Fifteen Days

07

Study locations

2 sites
  • Mona G Arafa
    New Cairo, Cairo 11837, Egypt
  • Mona G Arafa
    Cairo, 11837, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03615820
Lead sponsor
British University In Egypt
Responsible party
Mona Gamal Mohamed Afifi Arafa (Lecturer, British University In Egypt) — Principal investigator
First posted
Aug 6, 2018
Start date
Jan 1, 2018
Primary completion
Jan 30, 2018
Completion
Jan 30, 2018
Last update
Aug 6, 2018

Study contacts

Mona G Arafa, PhD
principal investigator · The British University in Egypt

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion